Intrapleural combination therapy with bevacizumab and cisplatin for non-small cell lung cancer‑mediated malignant pleural effusion
Reads0
Chats0
TLDR
Combined intrapleural therapy with bevacizumab and cisplatin was effective and safe in managing NSCLC-mediated MPE and it is proposed that VEGF expression levels in MPE could serve as a prognostic marker for bev ACIZumab therapy.Abstract:
Malignant pleural effusion (MPE) is a common complication of advanced non-small cell lung cancer (NSCLC). Bevacizumab, a humanized monoclonal antibody against vascular endothelial growth factor (VEGF), has been shown to be efficient in suppressing the accumulation of pleural fluid. However, whether intrapleural delivery of bevacizumab can be used to treat MPE remains unknown. The aim of the present study was to evaluate the efficacy and safety of combined intrapleural therapy with bevacizumab and cisplatin, an antineoplastic agent, in controlling MPE. A total of 72 NSCLC study subjects with MPE were randomly assigned to one of two groups. The first group received intrapleural bevacizumab (300 mg) with cisplatin (30 mg) therapy and the second group received intrapleural cisplatin (30 mg) therapy alone. Pleural fluid was collected from both groups prior to and following treatment. The levels of VEGF and carcinoembryonic antigen (CEA) in the pleural fluid were determined by ELISA. In 70 evaluable study subjects, the curative efficacy in the bevacizumab group was significantly higher than that found in the cisplatin group (83.33 vs. 50.00%, respectively; p<0.05). Therapy with combined bevacizumab plus cisplatin significantly reduced VEGF levels in the pleural fluid (p<0.01). In the bevacizumab group, the levels of VEGF in the pleural fluid were significantly lower compared to those of the cisplatin group after treatment, which showed greater efficacy (p<0.01). In addition, combination therapy showed greater efficacy in the patients with high levels of VEGF expression (p<0.01). There was no significant difference in grade III/IV adverse events between the two groups. All procedures were well tolerated by the patients. Combined intrapleural therapy with bevacizumab and cisplatin was effective and safe in managing NSCLC-mediated MPE. We propose that VEGF expression levels in MPE could serve as a prognostic marker for bevacizumab therapy.read more
Citations
More filters
Journal ArticleDOI
Cisplatin in cancer therapy: molecular mechanisms of action
Shaloam Dasari,Paul B. Tchounwou +1 more
TL;DR: This comprehensive review highlights the physicochemical properties of cisplatin and related platinum-based drugs, and discusses its uses (either alone or in combination with other drugs) for the treatment of various human cancers.
Journal ArticleDOI
ERS/EACTS statement on the management of malignant pleural effusions.
Anna C. Bibby,Anna C. Bibby,Patrick Dorn,Ioannis Psallidas,José M. Porcel,Julius Janssen,Marios Froudarakis,Dragan Subotic,P Astoul,Peter B. Licht,Ralph A. Schmid,Arnaud Scherpereel,Najib M. Rahman,Giuseppe Cardillo,Nick A Maskell,Nick A Maskell +15 more
TL;DR: The literature revealed that talc pleurodesis and indwelling pleural catheters effectively manage the symptoms of MPE and the LENT score was identified as a validated tool for predicting survival in MPE, with Brims' prognostic score demonstrating utility in mesothelioma prognostication.
Journal ArticleDOI
Antigen-presenting intratumoral B cells affect CD4+ TIL phenotypes in non-small cell lung cancer patients
Tullia C. Bruno,Peggy Ebner,Brandon Moore,Olivia G. Squalls,Katherine A. Waugh,Evgeniy Eruslanov,Sunil Singhal,John D. Mitchell,Wilbur A. Franklin,Daniel T. Merrick,Martin D. McCarter,Brent E. Palmer,Jeffrey A. Kern,Jill E. Slansky +13 more
TL;DR: A new role is demonstrated for TIL-Bs in NSCLC tumors in their interplay with CD4+ TILs in the tumor microenvironment, establishing them as a potential therapeutic target in NSClC immunotherapy.
Journal ArticleDOI
Interventions for the management of malignant pleural effusions: a network meta‐analysis
TL;DR: Network meta-analysis evaluating the rate of pleurodesis failure, suggested talc poudrage to be a highly effective method and provided evidence that it resulted in fewer pleurodenis failures than eight other methods and the majority of the secondary outcomes were reported descriptively in this review.
Journal ArticleDOI
Management of malignant pleural effusion: challenges and solutions
TL;DR: In this article, the authors examine patient outcomes that have been studied to date, address the question of which are most important for managing patients, and review the literature related to the expected value for money (cost-effectiveness) of indwelling pleural catheters relative to traditionally recommended approaches.
References
More filters
Journal ArticleDOI
The biology of VEGF and its receptors.
TL;DR: Vascular endothelial growth factor (VEGF) is a key regulator of physiological angiogenesis during embryogenesis, skeletal growth and reproductive functions and is implicated in pathologicalAngiogenesis associated with tumors, intraocular neovascular disorders and other conditions.
Journal ArticleDOI
Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid.
Donald R. Senger,Stephen J. Galli,Ann M. Dvorak,Carole A. Perruzzi,V. Susan Harvey,Harold F. Dvorak +5 more
TL;DR: Tumor ascites fluids from guinea pigs, hamsters, and mice contain activity that rapidly increases microvascular permeability, and this activity is secreted by these tumor cells and a variety of other tumor cell lines in vitro.
Journal Article
Humanization of an Anti-Vascular Endothelial Growth Factor Monoclonal Antibody for the Therapy of Solid Tumors and Other Disorders
L G Presta,Helen Hsifei Chen,S J O'Connor,Vanessa Chisholm,Y G Meng,L Krummen,M Winkler,Napoleone Ferrara +7 more
TL;DR: Rec recombinant humanized MAb V EGF is suitable to test the hypothesis that inhibition of VEGF-induced angiogenesis is a valid strategy for the treatment of solid tumors and other disorders in humans.
Journal ArticleDOI
Isolation of a tumor factor responsible for angiogenesis
TL;DR: It is suggested that blockade of this factor (inhibition of angiogenesis) might arrest solid tumors at a tiny diameter of a few millimeters.
Journal ArticleDOI
Management of malignant pleural effusions.
Veena B. Antony,Robert Loddenkemper,P. Astoul,C. Boutin,P. Goldstraw,Jeffery W. Hott,F. Rodriguez Panadero,Steven A. Sahn +7 more
TL;DR: Post mortem studies suggest that most pleural metastases arise from tumour emboli to the visceral pleural surface, with secondary seeding to the parietal pleura 1, 20, and other possible mechanisms include direct tumour invasion (in lung cancers, chest wall neoplasms, and breast carcinoma), haematogenous spread to parietal Pleura, and lymphatic involvement.
Related Papers (5)
Predicting survival in malignant pleural effusion: development and validation of the LENT prognostic score
Amelia O Clive,Amelia O Clive,Brennan C Kahan,Clare E Hooper,Clare E Hooper,Rahul Bhatnagar,Rahul Bhatnagar,Anna J Morley,Natalie Zahan-Evans,Oliver J Bintcliffe,Rogier C. Boshuizen,Edward T.H. Fysh,Claire Tobin,Andrew R L Medford,John E Harvey,Michel M. van den Heuvel,Y. C. Gary Lee,Nick A Maskell,Nick A Maskell +18 more